Shares of Repligen Corporation (NASDAQ:RGEN) gained almost 9% on Thursday as volume quadrupled the 3 month daily average. There were no significant news releases or other significant events that could be detected.
Repligen develops novel therapeutics for the treatment of diseases of the central nervous system. It also sells Protein A products, which can be used for diagnostic purposes, including the detection of pancreatic disorders.
The company also conducts its own drug development programs for schizophrenia, bipolar disorder, and neurodegeneration. The $104 million company has $19.5 million in cash and no debt according to the latest Yahoo! financial data. Yearly Revenue has been increasing for the last 3 years, and in fact, the company recorded its first yearly profit in 2006.
Shares of Repligen closed at $3.43, a little more than 20% away from the 52-week high of $4.17.
Repligen has made BHI's BioWatch Alert List.